Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2017, Article ID 5074891, 4 pages
Case Report

Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring

1Internal Medicine, Easton Hospital, Easton, PA, USA
2Drexel University College of Medicine, Philadelphia, PA, USA
3Easton Hospital, PA, USA

Correspondence should be addressed to Munish Sharma; moc.liamg@demtnihsinum

Received 4 December 2016; Accepted 10 January 2017; Published 26 January 2017

Academic Editor: Antonio de Padua Mansur

Copyright © 2017 Munish Sharma and Daniel A. N. Mascarenhas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Ticagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS). According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic and nonfatal to the patient. We present a case of ticagrelor related second-degree type II heart block causing severe dizziness and diaphoresis that resolved after discontinuation of the medication.